spec sheet7 rows
Allyltestosterone A 17alpha-allyl derivative of testosterone first synthesized in 1936. Extending testosterone's 17alpha side chain to an allyl group abolishes its androgenic activity and converts the molecule into an antiandrogen; it was later patented as a topical antiandrogen and hair-growth inhibitor but was never marketed.
- Patented as a topical antiandrogen for hair growth, though it was never brought to market
- Parent structure for two marketed progestins, allylestrenol and altrenogest
Overview
One extra chemical group away from testosterone but functionally its opposite; it blocks androgen activity instead of boosting it.
Mechanism
The bulky 17alpha-allyl substitution sterically hinders full activation of the , so despite its testosterone-like steroid backbone the compound behaves as an androgen receptor rather than an . It also serves as the parent structure for two marketed progestins, allylestrenol and altrenogest.
receptor fingerprint
Antagonist
Safetyrisks and cautions, not medical advice
Allyltestosterone was never marketed or clinically tested in humans, so no established safety data exists.
Subjective profileweighing the evidence above
Nothing to take. It was patented as a topical antiandrogen for hair growth and then went nowhere, with no clinical testing and no safety data at all. Its real legacy is as the parent structure for two progestins that did reach the market. A structural footnote, not an option for hair loss.
Resources
This entry is here for reference.
Reviews
My notesprivate to this device
FAQ
What is Allyltestosterone used for?
It was patented as a topical antiandrogen and hair-growth inhibitor but was never marketed as an actual product.
How does Allyltestosterone work?
Its bulky 17alpha-allyl side chain blocks the androgen receptor rather than activating it, so despite looking like a testosterone derivative it acts as an antiandrogen.
Is Allyltestosterone well-researched?
No. It is documented mostly through patent literature and its role as the chemical parent of allylestrenol and altrenogest, not through clinical studies of its own.
Limitations of the evidence
- Never tested clinically in humans; no safety data exists
Notes and cautions
- Topical antiandrogens carry a theoretical risk of local hormonal side effects, though none are documented for this specific compound